Palm Harbor, Florida, United States In 1982 was created Oscor, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Palm Harbor. The fund was located in North America if to be more exact in United States.
The fund is generally included in less than 2 deals every year. The top activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Oscor, startups are often financed by Originate Ventures, Life Sciences Greenhouse of Pennsylvania, Ben Franklin Technology Partners of Northeastern Pennsylvania. The meaningful sponsors for the fund in investment in the same round are Originate Ventures, Life Sciences Greenhouse of Pennsylvania, Ben Franklin Technology Partners of Northeastern Pennsylvania.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Micro Interventional Devices. Among the most successful fund investment fields, there are Manufacturing, Medical Device.
The fund was created by Peter Osypka.
Related Funds
| Fund Name | Location |
| Amadeo | New York, New York, United States |
| Arborview Capital | Chevy Chase, Maryland, United States |
| Castrol innoVentures | Pangbourne, United Kingdom, West Berkshire |
| CEA Investissement | France, Ile-de-France, Paris |
| EGB Capital | - |
| ESRG Investments | - |
| GP Investments | Bermuda, Hamilton |
| GXS Foundation | China, Hangzhou, Zhejiang |
| Inter-Asia Venture Management | China, Hong Kong, Hong Kong Island |
| MadDog Ventures | Birmingham, Michigan, United States |
| Meruelo Capital Partners | California, Downey, United States |
| Ocean Energy | - |
| SIG | Chiyoda, Japan |
| ST Capital | - |
| START POINT | Japan, Shinjuku |
| Synthetic Genomics | California, La Jolla, United States |
| The Growth Fund | Australia, New South Wales, Sydney |
| UCLB | England, London, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 